Voluntary announcement - Ascentage Pharma's lisaftoclax granted breakthrough therapy designation in china for treatment-naive cll/sll
Filed with HKEX · Stock code 6855 ·
Watch Ascentage Pharma Group International's latest callAscentage Pharma Group International (HKEX:6855) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Ascentage Pharma Group International (HKEX:6855) Q2 2026 Earnings Call6ix is reading this filing.
View original source (HKEXnews)Ascentage Pharma Group International on 6ix
Story so far
- ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
- Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress
Earlier from Ascentage Pharma Group International
- Voluntary announcement - purchase of shares by the trustee for the purpose of the 2022 RSU scheme
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - acquisition of shares by the chairman and executive director
- Interim report 2026
- Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
Follow Ascentage Pharma Group International into a list and get an email when it puts out news.
Follow Ascentage Pharma Group International